Drug-Induced Lupus Erythematosus Questions & Answers

1. Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus. 1994 Dec. 3(6):455-9. [Medline].

2. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018 Jun 4. [Medline].

3. Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL, et al. Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis. 2018 Jun 1. [Medline].

4. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol. 2004 Mar-Apr. 22(2):157-66. [Medline].

5. Singh H, Sukhija G, Tanwar V, Arora S, Bhutani J. Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy. J Clin Diagn Res. 2016 Oct. 10 (10):OD06-OD07. [Medline].

6. Michaelis TC, Sontheimer RD, Lowe GC. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J. 2017 Mar 15. 23 (3):[Medline].

7. [Guideline] Finnish Medical Society Duodecim. Systemic lupus erythematosus (SLE). EBM Guidelines. Evidence-Based Medicine. 2007 Feb 20. Wiley Interscience. John Wiley & Sons:[Full Text].

8. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest. 1990 Mar. 85(3):968-72. [Medline]. [Full Text].

9. Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011 Mar. 164(3):465-72. [Medline].

10. Burlingame RW. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin Lab Med. 1997 Sep. 17(3):367-78. [Medline].

11. Zeitjian V, Mehdizadeh A. ANA-Negative Hydralazine-Induced Pericardial Effusion. Case Rep Med. 2017. 2017:3521541. [Medline].

12. Rubin RL. Drug-induced lupus. Expert Opin Drug Saf. 2015 Mar. 14(3):361-78. [Medline].

13. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008 Oct. 22(5):847-61. [Medline].

14. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009 Jan. 301(1):99-105. [Medline].

15. Costa MF, Said NR, Zimmerman B. Drug induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2007. 381-387.

16. Kelly D, O'Connell O, Henry M. Adalimumab-induced lupus serositis. BMJ Case Rep. 2015 Mar 4. 2015:[Medline].

17. De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus. 2006. 15(11):762-7. [Medline].

18. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2007 Jan. 19(1):61-6. [Medline].

19. Caramaschi P, Biasi D, Colombatti M, et al. Anti-TNF alpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int. 2006. 26:209-214.

20. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011 May. 50(5):619-25. [Medline].

21. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009 Jan. 301(1):99-105. [Medline].

22. Farver DK. Minocycline-induced lupus. Ann Pharmacother. 1997 Oct. 31(10):1160-3. [Medline].

23. Anyimadu H, Saadia N, Mannheimer S. Drug-induced lupus associated with rifabutin: a literature review. J Int Assoc Provid AIDS Care. 2013 May-Jun. 12(3):166-8. [Medline].

24. Toepfer M, Sitter T, Lochmuller H, Pongratz D, Muller-Felber W. Drug-induced systemic lupus erythematosus after 8 years of treatment with carbamazepine. Eur J Clin Pharmacol. 1998 Apr. 54(2):193-4. [Medline].

25. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol. 1997 Oct. 36(10):1089-94. [Medline].

26. Buchanan S, Rosemergy I, Healy P. Drug-induced subacute cutaneous lupus erythematosus due to treatment with interferon beta-1a. N Z Med J. 2013 Aug 2. 126(1379):98-101. [Medline].

27. Lis-Swiety A, Brzezinska-Wcislo L, Widuchowska M, Kucharz E. Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-a antagonists and rituximab therapy?. Immunopharmacol Immunotoxicol. 2013 Jun. 35(3):443-6. [Medline].

28. Pham HC, Saurat JH. Inhalation route inducing subacute cutaneous lupus erythematosus with tiotropium. Arch Dermatol. 2005 Jul. 141(7):911-2. [Medline].

29. Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013 Sep. 149(9):1071-5. [Medline].

30. Marchetti MA, Noland MM, Dillon PM, Greer KE. Taxane associated subacute cutaneous lupus erythematosus. Dermatol Online J. 2013 Aug 15. 19(8):19259. [Medline].

31. Lamond NW, Younis T, Purdy K, Dorreen MS. Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy. Curr Oncol. 2013 Oct. 20(5):e484-7. [Medline]. [Full Text].

32. Susano R, Caminal L, Ramos D, Díaz B. Amiodarone induced lupus. Ann Rheum Dis. 1999 Oct. 58(10):655-6. [Medline]. [Full Text].

33. McGuiness M, Frye RA, Deng JS. Atenolol-induced lupus erythematosus. J Am Acad Dermatol. 1997 Aug. 37(2 Pt 2):298-9. [Medline].

34. Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med. 1995 Nov 23. 333(21):1429. [Medline].

35. Chen JK, Chen TS, Lim P, Iqbal M. Drug-induced subacute cutaneous lupus erythematosus associated with doxorubicin. J Am Acad Dermatol. 2012 Dec. 67(6):e273-5. [Medline].

36. Miller KK, Chu J, Patel R, Kamino H. Drug-induced subacute cutaneous lupus erythematosus related to doxycycline. Dermatol Online J. 2011 Oct 15. 17(10):3. [Medline].

37. Alcántara-González J, Truchuelo-Díez MT, González-García C, Jaén Olasolo P. [Esomeprazole-induced subacute cutaneous lupus erythematosus]. Actas Dermosifiliogr. 2011 Oct. 102(8):638-40. [Medline].

38. Almagro BM, Steyls MC, Navarro NL, Domínguez EG, Acosta EH, Pérez MA, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. J Clin Oncol. 2011 Jul 10. 29(20):e613-5. [Medline].

39. Ravindran V. Lamotrigine-induced lupus: a case report. Int J Rheum Dis. 2011 Aug. 14(3):e47-8. [Medline].

40. Cabanillas M, Suárez-Amor O, Ramírez-Santos A, González-Vilas D, Núñez-Acevedo B, Monteagudo B, et al. Lamotrigine induced subacute cutaneous lupus erythematous. Dermatol Online J. 2012 Aug 15. 18(8):12. [Medline].

41. Seo JY, Byun HJ, Cho KH, Lee EB. Methimazole-induced bullous systemic lupus erythematosus: a case report. J Korean Med Sci. 2012 Jul. 27(7):818-21. [Medline]. [Full Text].

42. Berning SE, Iseman MD. Rifamycin-induced lupus syndrome. Lancet. 1997 May 24. 349(9064):1521-2. [Medline].

43. Hussain HM, Zakaria M. Drug-induced lupus secondary to sertraline. Aust N Z J Psychiatry. 2008 Dec. 42(12):1074-5. [Medline].

44. Wilkerson E, Hazey MA, Bahrami S, Callen JP. Golimumab-exacerbated subacute cutaneous lupus erythematosus. Arch Dermatol. 2012 Oct. 148(10):1186-90. [Medline].

45. Wee JS, Natkunarajah J, Marsden RA. A difficult diagnosis: drug-induced subacute cutaneous lupus erythematosus (SCLE) triggered by omeprazole in a patient with pre-existing idiopathic SCLE. Clin Exp Dermatol. 2012 Jun. 37(4):445-6. [Medline].

46. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. 2001 Sep. 137(9):1196-8. [Medline].

47. Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011 Aug. 165(2):335-41. [Medline].

48. Chatziralli IP, Kanonidou E, Chatzirallis A, Dimitriadis P, Keryttopoulos P. Episcleritis Related to Drug-Induced Lupus Erythematosus following Infliximab Therapy: A Case Report. Case Report Med. 2011. 2011:696285. [Medline]. [Full Text].

49. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009 Oct. 18(11):935-40. [Medline].

Catharine Lisa Kauffman, MD, FACP Georgetown Dermatology and Georgetown Dermpath

Catharine Lisa Kauffman, MD, FACP is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Royal Society of Medicine, Society for Investigative Dermatology, Women's Dermatologic Society

Disclosure: Nothing to disclose.

Caroline O Amin, MD Resident Physician, Department of Pediatrics, Connecticut Childrens Medical Center, University of Connecticut School of Medicine

Caroline O Amin, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association

Disclosure: Nothing to disclose.

Arden E Fredeking Georgetown University School of Medicine

Arden E Fredeking is a member of the following medical societies: American Medical Student Association/Foundation

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Ivan D Camacho, MD Dermatologist, Private Practice; Voluntary Assistant Professor of Dermatology, Department of Dermatology and Cutaneous Surgery, University of Miami, Leonard M Miller School of Medicine

Ivan D Camacho, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Florida Medical Association, International Society of Dermatology, Women's Dermatologic Society

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Consulting fee Consulting; Celgene Honoraria Safety Monitoring Committee; GSK - Glaxo Smith Kline Consulting fee Consulting; TenXBioPharma Consulting fee Safety Monitoring Committee

Craig A Elmets, MD Professor and Chair, Department of Dermatology, Director, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Craig A Elmets, MD is a member of the following medical societies: American Academy of Dermatology, American Association of Immunologists, American College of Physicians, American Federation for Medical Research, and Society for Investigative Dermatology

Disclosure: Palomar Medical Technologies Stock None; Astellas Consulting fee Review panel membership; Massachusetts Medical Society Salary Employment; Abbott Laboratories Grant/research funds Independent contractor; UpToDate Salary Employment; Biogen Grant/research funds Independent contractor; Clinuvel Independent contractor; Covan Basilea Pharmaceutical Grant/research funds Independent contractor; ISDIN None Consulting; TenX BIopharma Grant/research funds Independent contractor

Michael J Wells, MD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article